Renalytix publishes new real-world evidence on KidneyIntelX utility

Renalytix announces the release of new real-world evidence case studies published in the peer reviewed journal Diabetic Nephropathy entitled: "The Need for Risk Stratification in Type 2 Diabetes and Chronic Kidney Disease: Proposed Clinical Value of KidneyIntelX." The publication underscores the importance of enabling early risk assessment in diabetic kidney disease to reduce likelihood of progression to kidney failure and dialysis. This publication highlights the limitations of current tools commonly used in chronic kidney disease, CKD, management and how KidneyIntelX can optimize care with the examination of four patient cases under clinical management by four different physicians. Bioprognostic tools, such as KidneyIntelX, incorporate well-validated prognostic protein biomarkers integrated with key clinical variables from a patient’s health record can help predict rapid kidney function decline in these early-stage CKD patients, proactively optimize care, and change the trajectory of chronic kidney disease before severe or irreversible kidney damage occurs.